UnitedHealth (UNH) shares closed lower on Tuesday following reports that the company quietly sold stakes in its business units to private equity firms like KKR and Warburg Pincus last year, potentially generating up to $3.3 billion in additional profits. Most of these transactions took place in the fourth quarter, and the deals included buyback clauses, suggesting that UnitedHealth may have used them strategically to maintain its streak of beating earnings estimates for 60 consecutive quarters.
As a result of these reports, UnitedHealth stock has declined by more than 50% from its year-to-date high. The revelation that the company relied on discreetly selling stakes to meet earnings expectations raises concerns about the sustainability of its profit growth. While these transactions are not illegal, the timing and lack of explicit disclosure indicate an effort to mask rising medical costs and operational challenges.
These maneuvers could distort the company’s true financial health, potentially eroding trust in its long-standing earnings consistency. Additionally, the agreements with the private equity firms require UnitedHealth to repurchase the divested stakes at a higher price in the future, adding long-term liabilities that could impact cash flow and earnings quality.
The ongoing challenges facing UnitedHealth have not gone unnoticed by analysts. Despite the stock’s struggles, Wolfe Research maintains an “Outperform” rating on UNH, citing significant undervaluation. The forward price-earnings (P/E) multiple of less than 14x is well below the historical average, presenting an opportunity for investors.
However, in light of the company’s difficulties, Wolfe Research has lowered its price target on UNH to $330, indicating a potential upside of 14% from current levels. Other Wall Street firms also remain positive on UnitedHealth, with a consensus rating of “Moderate Buy” and a mean target of $360, suggesting a potential upside of nearly 24%.
While the stock may be trading at a discount, investors should consider the implications of UnitedHealth’s reported tactics to maintain earnings momentum. Transparency and trust are essential in the financial markets, and any perception of engineered results could further pressure UNH shares in the future.
In conclusion, UnitedHealth’s recent challenges highlight the importance of thorough due diligence and careful consideration of the underlying factors driving a company’s performance. As investors navigate the complexities of the healthcare sector, staying informed and remaining vigilant can help mitigate risks and capitalize on opportunities in the market.
